Development and supply of safe and effective vaccine for global public health

Research and Development

R&D Overview

The R&D Center of EuBiologics Co., Ltd leverages its in-house developed technology and experiences for vaccine development.
It successfully commercialized the first product, Euvichol® at the end of 2015 and expedites the R&D in order to launch additional
products including vaccines against enteric diseases and prevention of cancer.
Our primary goal is to develop high quality vaccines leveraging R&D capabilities and expertise in biotechnology,
in order to improve the global public health, in particular for children in low and middle income countries.


Below products are under development leveraging our technical expertise and experiences in vaccine development

NAME Research Non-Clinical PhaseⅠ PhaseⅡ PhaseⅢ Approval Launch
Typhoid conjugate

EuBiologics has successfully developed a next-generation typhoid conjugate vaccine that has longer-lived defenses
and higher efficacy by conjugating Vi and CRM197 to induce the B cells and T cells immune response.

EuTCV EuTCV close
Pneumococcal conjugate

A 15-valent pneumococcal vaccine in which 15 serotypes of pneumococcal polysaccharides
is conjugated to the CRM197 protein We decided to develop a pneumococcal vaccine because pneumococcal serotypes
are new and widely emerging with a high incidence rate and the highest resistance to antibiotics throughout the world

EuPCV EuPCV close
Meningococcal conjugate

The first 4-valent meningococcal vaccine produced in Korea, in which 4 serotypes
of meningococcal polysaccharide (A, C, W-135 and Y) are conjugated to the CRM197 protein.
This meningococcal vaccine has higher efficacy compared to existing polysaccharide meningococcal vaccines.

EuMCV EuMCV close
Botulinum toxin

Botulinum Toxin is a toxin produced only by the gram-positive anaerobic bacteria, Clostridium botulinum,
inducing temporary muscle paralysis by reversibly blocking the secretion of acetylcholine at a neuromuscular junction.

Cervical cancer

Cervical cancer is caused by certain types of human papillomavirus (HPV).
Currently more than 190 types of HPV have been identified, among which HPV 16 and 18, the high-risk types,
account for approximately 70% of cervical cancers.
2-valent and 4-valent HPV vaccines are approved and marketed in Korea.
EuBiologics is currently in the process of developing a HPV vaccine by applying EcML (adjuvant)
to a 4-valent (HPV 16/18/6/11) antigen.

* Herpes Zoster Virus
(HZV) vaccine

Varicella caused by Varicella Zoster Virus (VZV) remains dormant in a nerve ganglion and becomes active again
when the immune system gets weak. While approximately 60% of patients are in their 50s or older, VZV occurs in people
with a weak immune system or under excessive stress, causing rashes and blisters.
Currently, two types of herpes zoster virus vaccines have been approved and marketed in Korea,
but their effective rates are around 50%.
EuBiologics is in the process of developing a vaccine with a 90% or higher effective rate, using EcML and CoPoP.

* Respiratory Syncytial
Virus (RSV) vaccine

Eubiologics is in the process of developing liposome nanoparticle-based RSV vaccines
by combining with RSV vaccine antigens an Immune-enhancing system in a form of liposomal nanoparticles
containing CoPoP (antigen display technology) and MPLA (TLR4 agonist).
Respiratory Syncytial Virus (RSV) is a virus that causes severe respiratory infection, mostly in older adults,
infants and anyone with a weak immune systemgreat.
In particular, there has been a great increase in cases of RSV infection in postnatal care centers
where infants are densely populated; yet there is no existing vaccine.

* Alzheimer’s disease

Alzheimer’s disease is the most common cause of dementia and accounts for 75% of all patients with dementia.
There are currently no medicines or vaccines for Alzheimer’s disease;
it is an irreversible, progressive brain disorder that could eventually lead to death.
Although its causes have not yet been clearly identified,
there are some hypotheses that amyloid protein or tau protein could be the main cause.
EuBiologics is aiming to develop an Alzheimer’s disease vaccine using (i) an amyloid/tau compound antigen,
(ii) CoPoP that can display the antigen effectively and (iii) EcML that may increase immunogenicity.


EuBiologics has completed development of a COVID-19 vaccine by producing recombinant antigens
as a result of targeting spike protein (RBD) and by using EcML, a TLR4 agonist (MPLA) and liposome-based
adjuvant that includes the CoPoP technology which binds antigens to the surface of liposomes,
thereby targeting SARS-CoV-2 spike protein and generating antibodies to COVID-19.
EuBiologics is the only company throughout the world that has managed to develop such technology.


* If you’re interested in potential collaboration of our pipeline products, please feel free to contact R&D Center.
* Please click the product name for details.
* Under development in the Joint Venture, EUPOP Life sciences based in USA